NVO
HEALTHCARENovo Nordisk
$45.76+0.89 (+1.98%)PRE
Live · NYSE · May 9, Close
AI Insight
What's Moving NVO Today?
No stock-specific AI insight has been generated for NVO yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$34.58$77.68
$45.76
Fundamentals
Market Cap$202.8B
P/E Ratio10.6
EPS$4.30
Dividend Yield0.04%
Dividend / Share—
ROE0.7%
Profit Margin0.4%
Debt / Equity—
Trading
Volume30.9M
Avg Volume (10D)—
Shares Outstanding3.36B
NVO News
56 articles- Is This News From Novo Nordisk a Warning for Eli Lilly Shareholders?Motley Fool·May 9, 2026
- Amazon Pharmacy Access To Ozempic Pills Tests Novo Nordisk Pricing PowerYahoo Finance·May 9, 2026
- Sector Update: Healthcare Stocks Lower Late AfternoonYahoo Finance·May 8, 2026
- Eli Lilly's Retatrutide Is So Hot, The Unlaunched Weight-Loss Drug Is Already Getting Knocked OffYahoo Finance·May 8, 2026
- Novo Nordisk India Sales Jump After Price CutsYahoo Finance·May 8, 2026
- GLP-1 battle heats up between Eli Lilly and Novo NordiskYahoo Finance UK·May 8, 2026
- European Stocks Decline in Friday Trading; Middle East Ceasefire Tenuous Amid Rising US-Iran TensionsYahoo Finance·May 8, 2026
- Prothena Posts Q1 Earnings as Revenues Surge on Milestone PaymentYahoo Finance·May 8, 2026
- Wegovy pill on track for blockbuster status as Novo Nordisk navigates crowded GLP-1 marketProactive Investors·May 8, 2026
- Novo Nordisk India Sales Jump 40% As Generic Pressure BuildsYahoo Finance·May 8, 2026
- Novo’s CEO champions “record-breaking start” for Wegovy pill in US marketPharmaceutical-technology·May 8, 2026
- Lexicon Pharmaceuticals Q1 Earnings Call HighlightsMarketbeat·May 8, 2026
- Is Novo Nordisk (NYSE:NVO) Pricing Look Interesting After Recent Share Price Rebound?Yahoo Finance·May 8, 2026
- A Look At Novo Nordisk (CPSE:NOVO B) Valuation After Oral Wegovy Success Lifts 2026 OutlookYahoo Finance·May 7, 2026
- Prothena Reports First Quarter 2026 Financial Results and Business HighlightsYahoo Finance·May 7, 2026
- Novo Nordisk Surges 9.2% As Wegovy Pill Fuels MomentumYahoo Finance·May 7, 2026
- Forget Eli Lilly: These 2 Stocks Have More UpsideMotley Fool·May 7, 2026
- Amazon Adds Same-Day Ozempic Pill DeliveryYahoo Finance·May 7, 2026
- Amazon Expands GLP 1 Push With Ozempic PillYahoo Finance·May 7, 2026
- Amazon adds Ozempic pill to pharmacy kiosks with same-day deliveryQz·May 7, 2026
- Amazon Pharmacy Expands Access to New Ozempic® Pill via Same-Day Delivery, KiosksYahoo Finance·May 7, 2026
- Lilly’s Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It PermanentInvesting.com·May 1, 2026
- Retatrutide Crosses the Surgical Threshold, but the Real Race Has Just StartedGlobeNewswire Inc.·Apr 29, 2026
- Is Eli Lilly Stock Undervalued at $870? 1 Top Wall Street Analyst Thinks SoThe Motley Fool·Apr 28, 2026
- Novo Nordisk to present new data on Wegovy®, women with obesity and next-generation weight loss treatments at European Congress on ObesityGlobeNewswire Inc.·Apr 28, 2026
- Is This Deal a Game Changer for Novo Nordisk?The Motley Fool·Apr 28, 2026
- Forget Weight Loss Drugs: Here's An Even Better Reason to Invest in Eli LillyThe Motley Fool·Apr 28, 2026
- Novo Nordisk A/S - share repurchase programmeGlobeNewswire Inc.·Apr 27, 2026
- Fangzhou Publishes 2025 Annual Report, Advancing AI-Powered Chronic Care Strategy for 2026GlobeNewswire Inc.·Apr 27, 2026
- Is This Tech Giant the Next Potential Winner in the GLP-1 Weight Loss Boom?The Motley Fool·Apr 25, 2026
- Why Eli Lilly Stock Flopped on FridayThe Motley Fool·Apr 24, 2026
- Forget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug WinsThe Motley Fool·Apr 23, 2026
- This Drug Stock Has Crushed the S&P 500 Over the Last DecadeThe Motley Fool·Apr 18, 2026
- Kailera Therapeutics Debut Marks Largest Biotech IPO Since 2021 Amid Weight Loss RaceBenzinga·Apr 17, 2026
- China Diabetes Devices Market Forecast and Company Analysis Report 2026-2034 Featuring Roche, Abbott Laboratories, Novo Nordisk, BD, Medtronic, Eli Lilly, and SanofiGlobeNewswire Inc.·Apr 17, 2026
- Is Viking Therapeutics the Ultimate Millionaire-Maker Obesity Stock for 2026?The Motley Fool·Apr 17, 2026
- Prediction: This 1 Thing Could Cement Eli Lilly's Leadership in the Billion-Dollar Weight Loss Drug MarketThe Motley Fool·Apr 16, 2026
- The $1 Trillion Race: Why Eli Lilly Is Leaving Novo Nordisk in the DustThe Motley Fool·Apr 15, 2026
- GoodRx Rallies As Wegovy HD Rollout Targets Self-Pay MarketBenzinga·Apr 15, 2026
- Novo Nordisk Expands AI Push With ChatGPT Parent OpenAIBenzinga·Apr 14, 2026
Price Data
Open$46.31
Previous Close$44.87
Day High$47.55
Day Low$45.53
52 Week High$77.68
52 Week Low$34.58
52-Week Range
$34.58$77.68
$45.76
Fundamentals
Market Cap$202.8B
P/E Ratio10.6
EPS$4.30
Dividend Yield0.04%
Dividend / Share—
ROE0.7%
Profit Margin0.4%
Debt / Equity—
Trading
Volume30.9M
Avg Volume (10D)—
Shares Outstanding3.36B
About Novo Nordisk
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
HEALTHCAREDRUG MANUFACTURERS - GENERAL
Company Details
Security TypeStock
ExchangeNYSE
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - GENERAL
CIK—
Composite FIGI—
Share Class FIGI—